Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J/DePuy Charite

This article was originally published in The Gray Sheet

Executive Summary

Artificial spinal disc is on track for a U.S. debut in the first half of 2005 after J&J/DePuy's submission of a PMA application for the first-of-its-kind device Feb. 9. The filing includes data from a 375-patient, 15-center trial with two-year follow-up on 90% of patients. The study aimed to demonstrate equivalency to traditional spinal fusion. However, the firm claims that in many cases patients achieved superior outcomes with the artificial disc. J&J acquired the technology from Link Spine Group in May 2003 (1"The Gray Sheet" May 12, 2003, p. 22)...

You may also be interested in...



J&J/DePuy Charite Artificial Spinal Disc Restores Height By 7.2 MM Average

Johnson & Johnson/DePuy's Charite artificial lumbar disc restores disc space height from an average of 5.7 mm pre-implant to 12.9 mm at 24 months

Biomet’s Interpore Purchase Creates $200 Mil. Spinal Devices Business

Biomet will expand its spinal franchise by nearly one third and gain artificial disc technology via the $280 mil. cash acquisition of Interpore, announced March 8

J&J/DePuy Projects SB Charite Artificial Lumbar Disc PMA Submission In 2004

J&J/DePuy Acromed will establish itself as a player in the nascent artificial spinal disc market through the purchase of Link Spine Group for $325 mil., plus additional milestone payments

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel